Loading data for ELVN — first visit, this takes a few seconds.
Enliven Therapeutics, Inc. (ELVN)
NasdaqGS: ELVN
· Real-Time Price · USD
59.32
-0.33 (-0.55%)
At close: Sep 11, 2026, 8:00 PM
54.32
+0.00%
After-hours: 4:10 PM
The price, the headline numbers and the latest news, in one place.
Enliven Therapeutics, Inc. (ELVN) Stock Price, Analysis & Data
No data available
| Bid | 42.77 |
| Market Cap | 3.98B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -106M |
| 0.24 | |
| -1.65 | |
| n/a | |
| -23.23 | |
| P/B (ttm) | 4.45 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 11, 2026 |
| Ask | 75.77 |
| Volume | 1,113,059 |
| Avg. Volume (20D) | 1,421,344 |
| Open | 59.69 |
| Previous Close | 59.65 |
| Day's Range | 58.97 - 59.89 |
| 52-Week Range | 14.79 - 62.32 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibito...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2020
Employees 67
Stock Exchange NasdaqGS
Ticker Symbol ELVN
Financial Performance
In 2025, Enliven Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -103.69M, an increase of 16.48%.
Financial StatementsEarnings Surprise
Enliven Therapeutics has released their quarterly earnings on Aug 5, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.49 misses estimates by -0.11, with 0.00% YoY growth.
Enliven Therapeutics, Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2